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licenses/by/4.0/).Abstract Background: Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin)
for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will sur-
vive long term. Paediatricians successfully reduce toxicities by using lower bleomycin doses
and substituting carboplatin for cisplatin, while testicular and paediatric immature teratomas
(ITs) are safely managed with surgery alone.
Aim: The aim was to determine whether reduced-toxicity treatment could rationally be
extended to patients older than 18 years.
Methods: Multicentre cohort study was carried out in four large UK cancer centres over 12
years.olecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square,
uk (M. Lockley).
o this work.
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C. Newton et al. / European Journal of Cancer 113 (2019) 19e2720Results: One hundred thirty-eight patients were enrolled. Overall survival was 93%, and event-
free survival (EFS) was 72%. Neoadjuvant/adjuvant chemotherapy (82% BEP) caused 27
potentially chronic toxicities, and one patient subsequently died from acute lymphoblastic
leukaemia. There was no difference in histology, stage or grade in patients />18 years,
and EFS was not different in these age groups (18:28% and >18:28%; log-rank
PZ 0.96). Histological subtype powerfully predicted EFS (log-rank PZ 4.9  107). Neoad-
juvant/adjuvant chemotherapy reduced future relapse/progression in dysgerminoma (n Z 37,
chemo:0% vs. no chemo:20%), yolk sac tumour (n Z 23, 26.3% vs.75%) and mixed germ cell
tumour (nZ 32, 40%vs.70%) but not in IT (nZ 42, 33% vs.15%). Additionally, we observed
no radiological responses to chemotherapy in ITs, pathological IT grade did not predict EFS
(univariate hazard ratio 0.82, 95% confidence interval: 0.57e1.19, PZ 0.94) and there were no
deaths in this subtype.
Conclusion: Survival was excellent but chemotherapy toxicities were severe, implying signifi-
cant overtreatment. Our data support the extension of reduced-toxicity, paediatric regimens
to adults. Our practice-changing findings that IT was chemotherapy resistant and pathological
grade uninformative strongly endorse exclusive surgical management of ovarian ITs at all
ages.
ª 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ovarian germ cell tumours (OvGCTs) are very rare,
comprising only 1e2% of ovarian malignancies [1,2].
They usually present at an early stage in children and
young adults, are generally chemotherapy sensitive and
outcomes are excellent even in metastatic disease [3,4].
Fertility-sparing surgery is established as standard of
care [5e7], but clinical trial data are severely lacking
regarding the adjuvant management of these rare tu-
mours in adult women, and progress has lagged behind
other cancers [8].
OvGCTs are divided into histological subtypes ac-
cording to the World health Organisation pathological
classification: primitive germ cell tumours
(dysgerminoma [Dys], yolk sac tumour [YST] and mixed
germ cell tumour [MGCT]) and the teratomas (imma-
ture teratoma [IT] and mature teratoma [MT]) [9]. IT is
further divided into three grades based on the amount of
primitive neuroectodermal tumour (PNET). Prognosis
varies by subtype, Dyss and teratomas having particu-
larly favourable outcomes [10,11]. Despite these differ-
ences, the National Comprehensive Cancer Network [6]
recommends adjuvant BEP chemotherapy (bleomycin,
etoposide and cisplatin) for all histologies in adults,
except stage I Dys and stage I, grade 1 ITs. Recent
European Society of Medical Oncology (ESMO)
guidelines [7] describe active surveillance protocols for
subsets of patients with stage I disease and normal
postoperative tumour markers. BEP toxicities are sig-
nificant, including pulmonary fibrosis, hypertension,
permanent hearing damage, chronic kidney disease,
Raynaud’s phenomenon and an increase in secondary
cancers such as leukaemia [12]. Late effects are partic-
ularly concerning in these young women with a veryhigh likelihood of cure and some advocate close sur-
veillance for all stage I OvGCTs, regardless of histology,
with chemotherapy salvage if progression occurs [13,14].
Reduced-toxicity treatments are already established
in paediatric and male GCTs. JEB (carboplatin, etopo-
side and bleomycin) has replaced BEP in children [15],
while adjuvant treatment of male seminomas (Dys
equivalent) is with either carboplatin (AUC 7) or
radiotherapy (20 Gy/10 fractions) [16,17]. These strate-
gies have not been tested in women. The most obvious
discrepancy is in the management of ovarian ITs:
adjuvant BEP is recommended for adults (except grade
1, stage IA) [6], whereas in children, evidence supports
postoperative surveillance for all IT stages and grades
[18]. This clearly presents a dilemma in the treatment of
18-year-old females [19]. The Malignant Germ Cell In-
ternational Collaborative (MaGIC) conducted a retro-
spective analysis of IT data from paediatric (Children’s
Oncology Group and Children’s Cancer and Leukaemia
Group) and adult (Gynecologic Oncology Group) clin-
ical trials [20]. Adults had higher stage, higher grade and
lower complete debulking rates, and their overall sur-
vival (OS) was marginally lower (93% vs 99%), despite
much higher administration of adjuvant chemotherapy
(81 of 81 adult patients vs 8 of 98 children). Although it
was not possible to determine whether the survival dif-
ference was due to trial eligibility or to disease biology,
this analysis does question the overall efficacy of
chemotherapy in ovarian ITs.
In view of the marked differences in adult and pae-
diatric practice, the serious toxicities associated with
current chemotherapy regimens and the paucity of
available clinical data, we conducted a multicentre
retrospective cohort study of adult and paediatric pa-
tients treated in four large UK cancer centres over 12
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chemotherapy in the initial management of OvGCTs





We analysed all OvGCTs at Barts Health NHS Trust,
University College Hospital and University Hospitals
Bristol NHS Foundation Trust, as well as adult patients
presenting to the Royal Marsden Hospital, between 01
January 2005 and 31 December 2016. Hospital ethical
approval was obtained, and data sharing agreements
were established between partner organisations in
accordance with the European General Data Protection
Regulations. All primary gynaecological Dys, YST, IT
and MGCT were identified from pathology and surgical
databases. We excluded only one patient because of
insufficient clinical information. Patient details were
obtained via extensive review of hospital notes and
computer records. Histology was reviewed centrally by
supraregional specialists in each of the four individual
cancer centres. All pathology reports were then reviewed
again by an expert germ cell tumour pathologist
(D.M.B.) to ensure accurate interpretation of local
specialist pathology reports.
Yolk sac tumour 23
Immature teratoma 42
PNET 4
Mixed germ cell tumour 32
Total 138
Age of patients Median (range)
Dysgerminoma 21 (11e47)
Yolk sac tumour 27 (14e69)
Immature teratoma 26 (11e44)
PNET 23 (9e32)
Mixed germ cell tumour 24.5 (8e76)
All patients 23.5 (8e76)
First-line chemotherapy n (%)
Dysgerminoma 22 (59%)
Yolk sac tumour 19 (82%)
Immature teratoma 9 (21%)
PNET 4 (100%)
Mixed germ cell tumour 22 (69%)















Not known 2 (67%)
Total 762.2. Statistical analysis
Statistical methods were documented in a prespecified
statistical analysis plan. Univariable and multivariable
Cox regression models were used to analyse the effects
of covariates (age, Fe´de´ration Internationale de Gyne´-
cologie et d’Obste´trique (FIGO) stage, histology, grade,
and chemotherapy) on the primary end-point, event-free
survival (EFS). In the multivariable analysis, grade was
excluded as it was not statistically significant and
chemotherapy was also excluded as it was a non-
randomised intervention rather than a baseline tumour
characteristic. EFS was defined as the time from pri-
mary surgery until the date of documented relapse or
progression of any germ cell histology (including disease
progression while awaiting adjuvant chemotherapy).
The age cut-off of paediatric and adult practice was 18
and > 18 years. The accepted upper age limit for
adolescent and young adult (AYA) practice is 39 years,
and thus, we defined a second age cut-off at 40 years to
distinguish older adults from AYA. In view of the small
patient numbers, neoadjuvant and adjuvant chemo-
therapies were combined for the purposes of statistical
analysis and are collectively referred to here as ‘first-line
chemotherapy’. Patients were censored on the date of
the last follow-up or death. Schoenfeld residuals were
examined to determine if Cox modelling was an
appropriate analytical approach. Spearman’s rankcorrelation was estimated pairwise for all variables.
KaplaneMeier survival curves were plotted, and P-
values from the log-rank or ManteleHaenszel test were
reported. All applied statistical tests were two sided, and
P < 0.05 was considered significant. Analyses were
performed in R version 3.4.3 [21].3. Results
3.1. Patient characteristics
We enrolled 138 patients (Table 1). One patient had
primary endometrial MGCT, but the remainder had
primary OvGCTs. Two patients with raised aFP
(1178kIU/L and 42,000kIU/L) received neoadjuvant
chemotherapy without diagnostic biopsy. Both were
found to have MT at surgery after completion of
chemotherapy and were grouped with MGCT for sub-
sequent statistical analysis. There was a preponderance
of early-stage disease, with only 38 stage III/IV patients
(28% total). All but one patient had surgery, which was
fertility sparing in 88% cases (120 of 137). The small
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oophorectomy or hysterectomy were either older (40
years: 6 of 17 patients) or had undergone prophylactic
surgery for underlying genetic syndromes (5 of 17 pa-
tients). A further six patients all had disease that had
spread beyond the ovaries (FIGO II/III/IV).
3.2. Overall and event-free survival
Median follow-up was 56.6 months (range: 11 days-16.5
years). The OS rate was 93%. Nine patients (7%) died of
disease and one died of acute lymphoblastic leukaemia
(ALL), which was presumed to be treatment related.
EFS was 72%, and relapse/progression events occurred
in 39 patients (28%). As expected, residual disease after
surgery was associated with disease relapse (Suppl.
Fig. 3; log-rank test P Z 3.0  105). In the Cox
regression analysis (Table 2), neither age (univariable
hazard ratio [HR] 1.03, 95% confidence interval [CI]
1.0e1.05, PZ 0.09; multivariable PZ 0.25) nor FIGO
stage (univariable HR 1.31, 95% CI 1.00e1.704,
P Z 0.051; multivariable P Z 0.53) was significantly
associated with EFS, although EFS was significantly
different when FIGO stage I was compared with all
other stages combined (Fig. 1A; log-rank test PZ 0.03).
In contrast, histological subtype strongly predicted
outcome (Table 2; univariable P Z 5.8  105 and
Fig. 1B; log-rank test P Z 4.9e-07).
3.3. Age
Adult patients (>18 years) made up 72% of cases (99 of
138). A greater proportion of women older than 18 years
received chemotherapy (46%  18 vs. 59% > 18), despite
there being no difference in the disease stage (Table 3;
proportions test c2 Z 5.87, d.f. Z 3, P Z 0.12) or
histological subtype (Table 3; proportions test
c2 Z 4.06, d.f. Z 4, P Z 0.40) when patients 18
and > 18 years were compared. There was no significantTable 2
Univariable and multivariable Cox regression analysis.
Predictor Univariable
HR (95% CI) LR c2 test d.f., p-va
Histology, Dys 1 Ref. 24.68 4, 5.8e-0
Histology, IT 3.02 (0.80, 11.46)
Histology, YST 5.06 (1.34, 19.09)
Histology, MGCT 8.87 (2.57, 30.55)
Histology, PNET 19.69 (4.35, 89.10)
Age (years) 1.03 (1.0, 1.05) 2.84 1, 0.09
Chemotherapy, yes 0.84 (0.45, 1.58) 0.29 1, 0.59
Stage (linear) 1.31 (1.01, 1.70) 3.82 1, 0.05
Grade 0.824 (0.570, 1.193) 1.17 1, 0.28
Age*stage
LR c2 test (d.f., p)
c-index (95% CI)
HR, hazards ratio, CI, confidence interval, LR c2, log-rank chi-squared te
noma; IT, teratoma; YST, yolk sac tumour; MGCT, mixed germ cell tumdifference in EFS between these age groups (log-rank
P Z 0.96, not shown).
Only 11 women were 40 years old. Most women
40 years presented with higher stage disease (Table 3),
and they were more likely to receive first-line chemo-
therapy (73%  40 compared with 55% overall). Despite
this, their EFS was significantly worse than younger
patients (Fig. 1C; HR 3.30, 95% CI 1.26e8.67,
P Z 0.02) and OS rate was only 55% (5 of 11 women
40 years died of their disease) compared with 93% for
the entire cohort.3.4. Chemotherapy use and toxicity
First-line chemotherapy (neoadjuvant or adjuvant) was
administered to 55% patients (76 of 138) and was more
likely to be given in higher stage disease (Table 1).
Chemotherapy was most commonly adjuvant (79%).
Only 16 patients received neoadjuvant chemotherapy, 12
of whom had stage III/IV disease (Suppl. Fig. 1). BEP
was used most frequently, accounting for 82% (62 of 76)
of cases, 11% received JEB (8 of 76, all aged 18 years)
and only one patient with IIIC PNET received a non-
platinumecontaining regimen (VIDE: vincristine, ifos-
famide, doxorubicin and etoposide).
Chemotherapy caused significant short- and long-
term toxicity (Table 4). This retrospective review will
have only identified severe, clinically significant toxic-
ities and so likely underestimates the true extent of
treatment-related side-effects. Nonetheless, we observed
27 potentially chronic toxicities in 22 patients including
kidney injury (n Z 2), cardiac failure (n Z 1), tinnitus
or hearing loss (nZ 9), bleomycin lung toxicity (nZ 4)
and peripheral neuropathy (n Z 11). One 14-year-old
patient died of ALL 2 years after surgery and adjuvant
JEB for stage IIIA MGCT (Dys and YST). In view of
these severe toxicities, and the powerful influence of
histology on EFS (Table 2 and Fig. 1B), we investigatedMultivariable
lue c-index HR (95% CI) Dc2 (d.f.) p-value





0.53 0.934 (0.87, 1.00) 1.32 (1) 0.25
0.53
0.59 0.45 (0.22, 0.94) 0.40 (1) 0.53
0.55
1.03 (1.01, 1.05) 6.86 (1) 0.01
33.265 (7, 2.4e-05)
0.770 (0.677, 0.864)
st, d.f., degrees of freedom, c-index, Harrell’s c-index; Dys, dysgermi-
our; PNET, primitive neuroectodermal tumour.
Fig. 1. KaplaneMeier event-free survival. Event-free survival according to (A) FIGO stage, (B) histological OvGCT subtype, (C) patient
age at diagnosis and (D) grade of immature teratoma. OvGCT, ovarian germ cell tumour; Dys, dysgerminoma; IT, teratoma; YST, yolk
sac tumour; MGCT, mixed germ cell tumour; PNET, primitive neuroectodermal tumour; HR, hazard ratio; CI, confidence interval.
Table 3
Patient characteristics by predefined age cut-off.
Patient’s age
18 years, N (%) >18 years, N (%) 40 years, N (%)
Total patient number (138) 39 patients 99 patients 11 patients
Stage
I 25 (64%) 61 (62%) 3 (27%)
II, III, IV 14 (36%) 35 (35%) 7 (64%)
NK 0 3 (3%) 1 (9%)
Proportions test c2 Z 4.06, d.f. Z 3, p-value Z 0.12
Histology
Dys 12 (31%) 25 (25%) 1 (9%)
IT (total) 15 (38%) 27 (27%) 1 (9%)
Gd 1 7 7 1
Gd 2 2 13 0
Gd 3 6 7 0
YST 6 (15%) 17 (17%) 2 (18%)
PNET 1 3 0
MT 1 1 0
MGCT 4 (10%) 26 (26%) 7 (64%)
Proportions test c2 Z 4.06, d.f. Z 4, p-value Z 0.40
c2 ,chi-squared test, d.f., degrees of freedom; Dys, dysgerminoma; IT, teratoma; YST, yolk sac tumour; MGCT, mixed germ cell tumour; PNET,
primitive neuroectodermal tumour; MT, mature teratoma.
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Table 4
The number of occurrences of potentially chronic chemotherapy
treatmenterelated toxicities.






died of ALL 1
Total 27
ALL, acute lymphoblastic leukaemia.
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tological subtype.
3.5. Immature teratoma
IT was the most common histology (Table 1; 42 cases),
and this subtype was overwhelmingly low stage (32 of 42
patients stage IA/B) (Suppl. Fig. 2A). Most patients
were safely managed with surgery alone, and there were
no deaths in this group. Only nine of 42 patients with
ITs received first-line chemotherapy (Table 1), three
preoperatively (stage III, IV and unknown; discussed in
the following section) and six postoperatively (four stage
IA and two stage IC) treated patients. The incidence of
any teratoma recurrence (IT, MT and gliomatosis peri-
tonei) was not reduced by first-line chemotherapy,
occurring in three of nine (33%) chemotherapy-treated
patients compared with five of 33 (15%) chemo-
therapy-naı¨ve patients (Suppl. Tables 1 and 2). Because
this could be explained by the higher disease stage of
chemotherapy-treated patients (only three patients with
ITs did not have stage I disease and all three received
chemotherapy, Suppl. Fig. 2A), we examined chemo-
therapy efficacy in the four patients with ITs with
measurable disease prior to chemotherapy. This
included the three neoadjuvant patients listed previously
and one chemotherapy-naı¨ve patient who relapsed after
initial surgery.
A 34-year-old woman relapsed in the brain and two
other distant sites one year after initial surgery for stage
IA, grade 2 ITs. The brain mass was resected (grade 2
ITs) with residual disease at the operation site. She
received EP-OMB chemotherapy (etoposide, cisplatin,
vincristine, methotrexate and bleomycin) and intra-
thecal methotrexate with minor response on MRI brain
but no radiological response in the other two metastatic
sites. Both these metastases were resected (again grade 2
ITs), and she received postoperative ACE chemotherapy
(actinomycin, cyclophosphamide, etoposide). Her most
recent MRI brain was stable, and she was well at censor,
four years after her most recent surgery.
The other three patients (stage III, IV and unknown)
were all treated preoperatively. Two had no radiological
response to chemotherapy, and IT was confirmed on
subsequent surgical debulking. The only evidence of anychemotherapy response in ITs was in a 37-year-old in-
dividual presenting with abdominal pain, a rapidly
growing pelvic mass and urinary sepsis. Presentation
lactate dehydrogenase was 916, and a scanty diagnostic
biopsy of the mass revealed PNET elements consistent
with grade 3 ITs and a possible accompanying Dys,
suggesting that this patient might have actually had a
MGCT. Three cycles of BEP achieved only a 25%
radiological reduction and surgical debulking revealed
MT.
3.6. IT grade
Relapse and progression with any teratoma histology
(immature, mature and gliomatosis) occurred in all
grades of ITs (Gd1: 3/14, Gd2: 2/15 and Gd3: 3/13).
Additionally, immature elements were found at recur-
rence in patients who initially presented with all three
grades of ITs (Gd1: 1/14, Gd2:1/15 and Gd3: 1/13).
Strikingly, pathological IT grade did not predict EFS
(Table 2; univariable HR 0.82, 95% CI 0.57e1.19,
P Z 0.28: Fig. 1D; log-rank P Z 0.94).
3.7. Primitive germ cell tumours (Dys, YST and MGCT)
In marked contrast to the chemotherapy resistance of
ITs, radiological responses were observed in 10 of 10
pure Dys and four of five pure YST chemotherapy-naı¨ve
patients. Dys outlook was exceptionally good, with no
patient deaths and no relapses in any patient after first-
line chemotherapy (Suppl. Fig. 2B; 22 of 22 patients).
Relapse did occur in three of 15 patients with stage IA/B
Dys who were initially treated with surgery alone. All
three were salvaged with platinum-containing chemo-
therapy (Suppl. Table 1), and all were alive and disease
free 16, 65 and 117 months after relapse. Only four
patients with YST did not receive first-line chemo-
therapy: two stage IA and two stage IC (Suppl. Fig. 2C).
Of these four, three progressed very rapidly after initial
surgery at 53, 68 and 103 days. As with Dys, chemo-
therapy response in YST was excellent with all three of
these chemotherapy-naı¨ve relapses being successfully
salvaged with BEP. All three patients were disease free
31, 28 and 26 months after diagnosis of recurrence.
Further evidence of chemotherapy sensitivity in YST
came from the observation that relapse/progression
appeared to be reduced by chemotherapy overall (5 of
19; 26% chemo-treated vs. 3 of 4; 75% chemo-naı¨ve;
Suppl. Table 1) and that median time to relapse was
increased by first-line chemotherapy treatment (344 days
in chemotherapy-treated patients compared with 68
days in chemotherapy-naive patients; unpaired t-test,
P Z 0.07). Re-treatment of the five patients with YST
who relapsed after BEP treatment was less successful.
Only two of these five patients were salvaged by further
surgery and chemotherapy but both were still in remis-
sion at the censor date, two and eight years after
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tients eventually died of their disease. Two of these three
deaths occurred in the only two patients with YST who
were aged 40 years.
All but one MGCT had a yolk sac component to
their histology (29 of 30). Most patients (20 of 30)
received first-line chemotherapy (Suppl. Fig. 2D). Eight
of these chemotherapy-treated patients subsequently
relapsed (Suppl. Table 1), but the pathology of six of
these relapses revealed MTs and mature glial tissue only
and these patients were all salvaged with surgery alone.
Four MGCT patients died of disease. One 19-year-old
patient with stage IV disease died of rapid disease pro-
gression postoperatively before initiation of adjuvant
chemotherapy. The other three deaths were all in women
aged 40 years. Two of these patients relapsed with
confirmed YST (aFP rise  biopsy) and were not
salvaged by second-line treatment, while the third
declined further chemotherapy.
3.8. Primitive neuroectodermal tumours
Somatic transformation of ovarian teratomas is associ-
ated with a poor outcome. Five patients had PNET,
four at diagnosis and one at relapse. Only one was
successfully treated to complete remission with surgical
resection followed by GAMEC chemotherapy (GCSF,
actinomycin, methotrexate, etoposide, cisplatin). She
was disease free 5 years after diagnosis, confirming that
PNET can be salvaged with intensive combination
treatment [22].
4. Discussion
OvGCTs are a heterogenous group of rare diseases.
Clinical data are severely lacking, and progress has
lagged behind other cancers [8]. Paediatricians aim to
reduce late effects in these patients with a near certainty
of long-term cure, but until now, treatment-induced
toxicities have not been prioritised in adult practice,
and international guidelines still recommend BEP in
nearly all cases.
This cohort study is one of the few large studies to
investigate these exceptionally rare ovarian cancers. The
OS rate was excellent at 93% with a median follow-up of
56.6 months. However, we recorded 27 potentially
chronic toxicities in 76 chemotherapy-treated patients
and one probable chemotherapy-related death.
Together, this implies widespread overtreatment, and
so, reduction of BEP use is a priority. Recent ESMO
guidelines [7] now support surveillance of subsets of
patients with stage I OvGCTs. Four of the 22 patients
who experienced potentially chronic toxicities had stage
I disease and thus might have been spared chemo-
therapy altogether according to these new guidelines.This approach appeared safe in our series. We identified
25 patients with stage I Dys, YST and MGCT who were
initially managed without chemotherapy. Although 10
of these subsequently relapsed, all were salvaged with
platinum-containing chemotherapy (BEP/JEB in nine
patients) with or without further surgery. In agreement
with others [23], our study therefore endorses and ex-
tends this expectant policy by advocating the avoidance
of chemotherapy in all FIGO stage I patients.
In higher stage disease, paediatricians have already
reduced chemotherapy toxicity by the widespread and
accepted use of JEB in preference to BEP. We identified
no statistically significant differences in OvGCTs pre-
senting in patients younger and older than 18 years.
Comparable series have made similar observations
[24,25], providing a compelling rationale for also using
carboplatin-based chemotherapy in adult patients. This
approach has already been shown to be equivalent in
Dys [26] and is currently being tested in other patients
aged 11e25 years with other ovarian germ cell histol-
ogies in the AGCT1531 study [27]. In contrast, women
older than 40 years appeared to present with higher
stage disease and were more likely to receive first-line
chemotherapy, and their EFS and OS were signifi-
cantly worse than younger adults. Age over 40 years has
previously been identified as a poor prognostic factor
[28], and clinical trials should now determine whether
this reflects suboptimal treatment or underlying disease
biology with the ultimate aim of improving the survival
of this group of women.
Our most important and practice-changing finding
was that, compared to the excellent responses to
chemotherapy observed in the primitive germ cell tu-
mours, we found little evidence of response to chemo-
therapy in ITs. Although IT relapse and progression
occurred frequently, there were no deaths either in pure
ITs or in teratomatous relapse of MGCT and both were
effectively managed with surgery alone. Eight of the
nine patients with ITs who received chemotherapy were
>18 years. We now propose that these adult patients
might be spared the risks of BEP chemotherapy and
managed safely with surgery as is currently the case in
paediatric practice and for MT at all ages.
This clinical overlap between IT and MT is supported
by frequent genetic homozygosity in IT and MT, but not
in MGCT, indicating a common cellular origin of IT
and MT with likely biological similarities in these his-
tologies [29]. Developmental differences between ITs
and other OvGCT subtypes can also be inferred from
their more stable copy number profile and absence of
12p gain [30]. Furthermore, the observation that copy
number profiles do not differ according to the grade of
ITs [30] provides a biological explanation for our
intriguing observation that EFS was identical regardless
of the IT grade. This provocative finding differs from a
C. Newton et al. / European Journal of Cancer 113 (2019) 19e2726previous pooled analysis of clinical trial data by MaGIC
in which IT grade did predict future relapse [20]. This
discrepancy could be explained by small numbers and
retrospective analysis in both studies, and clinical trials
are required to resolve this issue. Nonetheless, we agree
with MaGIC that there was little evidence of chemo-
therapy response in any grade of ITs and thus question
the utility of the World Health Organisation patholog-
ical IT grade as a biomarker to direct patient care.
Finally, we confirmed that Dys was exquisitely
chemotherapy sensitive with clear evidence of radio-
logical response to chemotherapy, no relapses after
chemotherapy and no deaths at a median follow-up of
6.38 years. Later relapse of this histology is possible with
a high expectation of chemotherapy salvage as was the
case for one patient in our cohort. Single-agent, high-
dose carboplatin may therefore be an appropriate and
less toxic treatment for Dys, as is already established in
the histologically equivalent testicular seminoma.
In summary, our large, multicentre retrospective
cohort study has exposed significant overtreatment with
excellent survival but frequent debilitating and poten-
tially life-threatening toxicities. We have shown that
platinum-containing chemotherapy can safely be avoi-
ded in stage I disease and that the role of chemotherapy
in the management of ovarian ITs should be reviewed.
Treatment-induced toxicities would be further reduced
by using single-agent carboplatin in Dys, and based on
the clinical similarity between patients older and
younger than 18 years, we propose that clinical trials
should now compare BEP with carboplatin-based
chemotherapy, such as JEB, in YST-containing histol-
ogies at all ages. These practice-changing recommen-
dations will herald a new era in the management of these
inherently good prognosis cancers.Conflicts of interest statement
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